Magrey M, Wolin DL, Mordin MM, McLeod LD, Davenport EK, Hur P. US patient satisfaction with Secukinumab treatment among patients with both psoriatic arthritis and psoriasis: data from a web-based survey. Poster presented at the 2018 Winter Clinical Dermatology Conference; January 2018. Hawaii. [abstract] Skin: the journal of cutaneous medicine. 2018 Feb 23; 2(2018). doi: 10.25251/skin.2.supp.25
Glaser DA, Hebert AA, Fehnel S, DiBenedetti D, Nelson L, Drew J, Pariser DM. Confirmatory psychometric evaluation of the axillary sweating daily diary: a vaildated patient-reported outcome measure to assess axillary hyperhidrosis sweating severity. Poster presented at the 36th Fall Clinical Dermatology Conference; October 2017. Las Vegas, NV. [abstract] Skin: the journal of cutaneous medicine. 2017; 1(Suppl 93):s94. doi: 10.25251/skin.1.supp.93.
Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm. 2014 Apr;22(2):96-101. doi: 10.3109/09273948.2013.812222
Martel JN, Esterberg E, Nagpal A, Acharya NR. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm. 2012 Feb;20(1):18-26. doi: 10.3109/09273948.2011.633205.
Gittelman M, Brown TM, Holm-Larsen T, Persson BE. Comparison of the impact of degarelix and leuprolide on the health-related quality of life of patients with prostate cancer: results of a 12-month phase III clinical trial. UroToday International Journal. 2011 Dec 1;4(6):Art. 81.
Küçükdeveci AA, McKenna SP, Kutlay S, Gürsel Y, Whalley D, Arasýl T. The development and psychometric assessment of the Turkish version of the Nottingham Health Profile. Int J Rehabil Res. 2000 Mar 1;23(1):31-8.